-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike★Accelerate product launches! Customize a unique HCP detection method for the product ★The first TF-targeted ADC has been approved by the US FDA for the treatment of cervical cancerYimai Meng broke the news.
Click on the picture and sign up now September 24, 2021 / Yimai Ke News eMedClub News/ --Recently, Triumvira Immunologics announced that its TAC-T cell therapy has completed its first patient administration in a clinical trial.
This is an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors
.
Paul Lammer, CEO of Triumvira, said: “Although CAR-T cell therapy has made progress in hematological malignancies, there are still a large number of patients in solid tumors who need to prove the safety and effectiveness of the drug
.
TACTIC-2 trial The launch of Triumvira is an important milestone for Triumvira and an opportunity to establish a clinical proof-of-concept for TAC technology
.
With the establishment of a pipeline of candidate drugs for solid tumors, we look forward to the sharing of future progress
.
"The advantages of TCR-T since CAR-T cell therapy Turned out, it has achieved remarkable curative effects in a variety of blood diseases
.
However, the treatment of solid tumors fails to produce good results and is usually hindered by severe/lethal toxicity
.
These clinical results may be because CAR provides unnatural signals
.
The unnatural signal transduction properties of CAR lead to uncontrolled activation of T cells, which are then rapidly depleted in the malignant tumor microenvironment of solid tumors, and cannot effectively kill tumor cells
.
The TCR method enables T cells to identify selected targets and use natural signal transduction, which may be preferred in solid tumors, and some clinical activities against solid tumors have been demonstrated
.
However, TCR provides limited tumor cell recognition, mainly because it relies on histocompatibility complex (MHC) binding, which is often absent or down-regulated in cancer cells
.
Because MHC molecules can display peptide chains obtained from cell surface and intracellular proteins, TCRs can target more antigens than CARs
.
When TCR-T and CAR-T attack solid tumors at the same time, most of TCR-T can be combined with more tumor cells, and the drug distribution is more balanced, but there are still some TCR-Ts that cannot be combined with it, and CAR-T usually It will adhere to the outer layer of the tumor without penetrating into the interior, which is less effective
.
Triumvira’s TAC technology platform Triumvira Immunologics was co-founded by Dr.
Jonathan Bramson and Bloom Burton & Co of McMaster University in Canada in 2015.
It aims to develop a safer, more secure, than current cell therapy cancer treatment (including CAR-T and TCR-T ) More effective new T cell therapy
.
The TAC developed by Triumvira optimizes the defects of CAR and TCR.
Its proprietary TAC (T cell antigen conjugate) technology can cultivate a complete natural T cell receptor (TCR) to genetically modify T cells and transform these T cells.
Cells are redirected to target cancer antigens, thereby mediating tumor cell killing
.
▲The difference between TAC and CAR (picture source: Triumvira company official website) For more details, scan the QR code for a complete reading.
Since TAC itself does not have signal transduction capabilities, T cell activation is only mediated by endogenous natural TCR Therefore, the ability of TCR to conduct signals is naturally activated, so there will be no toxic side effects such as CRS and neurotoxicity caused by CAR-T cells
.
At the same time, TAC utilizes the complete anti-cancer potential of T cells, while retaining the natural control and safety mechanisms of cells, which may provide better T cell activation regulation
.
TAC molecules can be tailored to specific tumor targets and other extracellular or intracellular parts, optimized and fine-tuned for specific tumor types
.
In a sense, TAC is more similar to the “bridge” built between tumor antigens and TCR.
While using the natural mechanism of TCR, it bypasses the limitations of the major histocompatibility complex (MHC), so it can be more Extensively develop better therapeutic drugs in patients with solid tumors and hematological tumors
.
In summary, this year, two CAR-T cell therapies have been approved for marketing in China, namely Fosun Kate’s Akilunza injection and WuXi Junuo’s Regiorenza injection.
This CAR-T cell immunotherapy Set off an upsurge, will further promote the development of the field of cell therapy
.
Previously, the clinical data of TAC-T once aroused heated discussion.
With the accumulation of later clinical experience and the unremitting efforts of scientists, we look forward to this next-generation cell therapy to bring new treatments to patients
.
Recommended reading: With an investment of over 670 million yuan, Fosun Kate’s first CAR-T product Yikaida® was approvedYimai Meng revealed that two CAR-T therapies have been approved one after another, and domestic cell and gene therapies are gaining momentumYimai Meng broke the news for reference: 1.
https:// -Clinical-Trial2.
https://triumvira.
com/press-releases/triumvira-doses-first-patient-with-novel-t-cell-therapy-in-tactic-2-clinical-trial/ Statement: What this article covers It is only used to explore the cutting-edge progress of biomedicine and does not constitute any medical guidance.
If necessary, please go to a regular hospital for treatment
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
Click on the picture and sign up now September 24, 2021 / Yimai Ke News eMedClub News/ --Recently, Triumvira Immunologics announced that its TAC-T cell therapy has completed its first patient administration in a clinical trial.
This is an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors
.
Paul Lammer, CEO of Triumvira, said: “Although CAR-T cell therapy has made progress in hematological malignancies, there are still a large number of patients in solid tumors who need to prove the safety and effectiveness of the drug
.
TACTIC-2 trial The launch of Triumvira is an important milestone for Triumvira and an opportunity to establish a clinical proof-of-concept for TAC technology
.
With the establishment of a pipeline of candidate drugs for solid tumors, we look forward to the sharing of future progress
.
"The advantages of TCR-T since CAR-T cell therapy Turned out, it has achieved remarkable curative effects in a variety of blood diseases
.
However, the treatment of solid tumors fails to produce good results and is usually hindered by severe/lethal toxicity
.
These clinical results may be because CAR provides unnatural signals
.
The unnatural signal transduction properties of CAR lead to uncontrolled activation of T cells, which are then rapidly depleted in the malignant tumor microenvironment of solid tumors, and cannot effectively kill tumor cells
.
The TCR method enables T cells to identify selected targets and use natural signal transduction, which may be preferred in solid tumors, and some clinical activities against solid tumors have been demonstrated
.
However, TCR provides limited tumor cell recognition, mainly because it relies on histocompatibility complex (MHC) binding, which is often absent or down-regulated in cancer cells
.
Because MHC molecules can display peptide chains obtained from cell surface and intracellular proteins, TCRs can target more antigens than CARs
.
When TCR-T and CAR-T attack solid tumors at the same time, most of TCR-T can be combined with more tumor cells, and the drug distribution is more balanced, but there are still some TCR-Ts that cannot be combined with it, and CAR-T usually It will adhere to the outer layer of the tumor without penetrating into the interior, which is less effective
.
Triumvira’s TAC technology platform Triumvira Immunologics was co-founded by Dr.
Jonathan Bramson and Bloom Burton & Co of McMaster University in Canada in 2015.
It aims to develop a safer, more secure, than current cell therapy cancer treatment (including CAR-T and TCR-T ) More effective new T cell therapy
.
The TAC developed by Triumvira optimizes the defects of CAR and TCR.
Its proprietary TAC (T cell antigen conjugate) technology can cultivate a complete natural T cell receptor (TCR) to genetically modify T cells and transform these T cells.
Cells are redirected to target cancer antigens, thereby mediating tumor cell killing
.
▲The difference between TAC and CAR (picture source: Triumvira company official website) For more details, scan the QR code for a complete reading.
Since TAC itself does not have signal transduction capabilities, T cell activation is only mediated by endogenous natural TCR Therefore, the ability of TCR to conduct signals is naturally activated, so there will be no toxic side effects such as CRS and neurotoxicity caused by CAR-T cells
.
At the same time, TAC utilizes the complete anti-cancer potential of T cells, while retaining the natural control and safety mechanisms of cells, which may provide better T cell activation regulation
.
TAC molecules can be tailored to specific tumor targets and other extracellular or intracellular parts, optimized and fine-tuned for specific tumor types
.
In a sense, TAC is more similar to the “bridge” built between tumor antigens and TCR.
While using the natural mechanism of TCR, it bypasses the limitations of the major histocompatibility complex (MHC), so it can be more Extensively develop better therapeutic drugs in patients with solid tumors and hematological tumors
.
In summary, this year, two CAR-T cell therapies have been approved for marketing in China, namely Fosun Kate’s Akilunza injection and WuXi Junuo’s Regiorenza injection.
This CAR-T cell immunotherapy Set off an upsurge, will further promote the development of the field of cell therapy
.
Previously, the clinical data of TAC-T once aroused heated discussion.
With the accumulation of later clinical experience and the unremitting efforts of scientists, we look forward to this next-generation cell therapy to bring new treatments to patients
.
Recommended reading: With an investment of over 670 million yuan, Fosun Kate’s first CAR-T product Yikaida® was approvedYimai Meng revealed that two CAR-T therapies have been approved one after another, and domestic cell and gene therapies are gaining momentumYimai Meng broke the news for reference: 1.
https:// -Clinical-Trial2.
https://triumvira.
com/press-releases/triumvira-doses-first-patient-with-novel-t-cell-therapy-in-tactic-2-clinical-trial/ Statement: What this article covers It is only used to explore the cutting-edge progress of biomedicine and does not constitute any medical guidance.
If necessary, please go to a regular hospital for treatment
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
